Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


Consumer group alleges Fabry treatment collusion between drug makers, medical school

Knowledge Economy International says not all is as it seems between Sanofi, Shire and the Icahn School of Medicine at Mount Sinai

It may look like a case of taking advantage of the market — drug maker Sanofi dominates American treatment of Fabry disease, while rival drug maker Shire controls the European market. But one consumer advocacy group believes the two sides, as well as the Icahn School of Medicine at Mount Sinai, are colluding to keep competition down and prices up for the treatment worldwide.

Knowledge Economy International has urged the Federal Trade Commission’s (FTC) Antitrust Division in a letter to investigate the relationship between Sanofi and Shire. The organization writes that Fabry patients are losing because of potential collusion between the parties.

“U.S. patients are depending upon a single supplier for treatments, and are disadvantaged because there is both a lack of potential competition among suppliers and a less secure supply chain,” the letter says.

Antitrust claims are nothing new. However, how the two drug makers got to this point, and how the Icahn School of Medicine is involved, provides a new wrinkle for the FTC to snuff out.

As pointed out in the Wall Street Journal’s Pharmalot blog, the medical school developed the original Fabry treatment in conjunction with the U.S. National Institutes of Health and was awarded a patent on the medicine in the mid-1990s. Once developed, the school licensed exclusive rights to a drug company named Genzyme.



Choosing wisely: Practical considerations for choosing venues for IP disputes

GSK settlement calls for promotional practices reform

Italian health ministry seeks damages of $1.6 billion for Novartis and Roche collusion


Soon, though, Genzyme fell on hard times. In 2009, the company encountered serious manufacturing problems that led to a shortage of the drug. The FDA then asked Shire, which held European regulatory approval to market and sell a Fabry treatment, to apply for U.S. approval as well. Then, in 2011, the tide switched once again, as drug maker Sanofi purchased Genzyme. Simultaneously, the medical school began litigating to enforce its patents in Europe, attempting to snuff out Shire’s market share.

So were the two sides destined to battle back and forth? It seemed that way... until in May 2012, Shire suddenly withdrew its request for U.S. approval, while the medical school withdrew its patent litigation. And it’s these withdraws that Knowledge Economy International finds fishy.

“KEI asks the FTC to investigate the decision by Shire to withdraw its application to sell Replagal in the United States... to determine if a conspiracy existed whereby Shire agreed to withdraw its application to compete in the U.S. Fabry market if Mount Sinai granted a license to use an [National Institutes of Health]-funded invention in European markets,” the investigation request reads.

This case will be one to watch for in-house counsel moving forward, whether the FTC finds any evidence of collusion between the two parties.

Assistant Editor

author image

Zach Warren

Zach Warren is Assistant Editor of InsideCounsel magazine, where he oversees online content submissions and administers InsideCounsel's enewsletters. Zach specializes in new media and multimedia...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.